Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Overview
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Companies Involved in Therapeutics Development
HK inno.N Corp
KinDex Pharmaceuticals Inc
MorphoSys AG
Novopyxis Inc
Vicore Pharma AB
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Drug Profiles
(amlodipine besylate + valsartan) + atorvastatin calcium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KDT-501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MOR-107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NP-6A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize AGTR2 for Skin Inflammation and Inflammatory Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Agonize AGTR2 for Kidney Fibrosis, Liver Fibrosis and Myocardial Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VP-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VP-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VP-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Dormant Products
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Discontinued Products
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Product Development Milestones
Featured News & Press Releases
Oct 01, 2020: Vicore Pharma announces completion of patient enrollment in the COVID-19 ATTRACT trial
Sep 25, 2020: Robust effects of VP01 in human idiopathic pulmory fibrosis lung tissue
Aug 25, 2020: Vicore Pharma restarts mechanistic study with VP01 in systemic sclerosis
Jul 27, 2020: Vicore Pharma doses first COVID-19 patient in the ATTRACT study in India
Jun 23, 2020: Vicore Pharma expands recruitment base for the ATTRACT study
Jun 22, 2020: Vicore Pharma’s drug candidate VP01 demonstrates potential for significant benefit in severe pulmory hypertension
May 29, 2020: LifeArc awards ? 1.5 million grant to Vicore Pharma for the VP01 COVID-19 clinical study
May 05, 2020: Vicore pharma receives regulatory approval to start phase II clinical trial with VP01 (C21) in patients with IPF
Apr 28, 2020: Vicore Pharma gets regulatory approval to start phase II clinical trial with VP01 (C21) in patients with COVID-19, SARS CoV-2 infection
Mar 31, 2020: Vicore Pharma submits Letter of Intent for a clinical trial application for a phase II study in patients with COVID-19, SARS CoV-2 infection
Mar 30, 2020: Vicore submits clinical trial application for phase II trial with C21 in IPF
Dec 18, 2019: Update on progress for drug development program VP02 (IMiD)
Dec 18, 2019: Update on progress for drug development program VP01 (C21)
Oct 01, 2019: Update on progress in clinical lead program VP01 (C21)
Sep 06, 2019: Safe and well tolerated dose of C21 established in successful dose escalation phase 1 study
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020


List of Tables


Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indication, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by HK inno.N Corp, H2 2020
Pipeline by KinDex Pharmaceuticals Inc, H2 2020
Pipeline by MorphoSys AG, H2 2020
Pipeline by Novopyxis Inc, H2 2020
Pipeline by Vicore Pharma AB, H2 2020
Dormant Products, H2 2020
Dormant Products, H2 2020 (Contd..1), H2 2020
Discontinued Products, H2 2020